The Food and Drug Administration has updated the labels on certain HIV drugs to include a contraindication for lurasidone (Latuda), an antipsychotic medication.

Lurasidone is used to treat depressive episodes in bipolar I disorder (bipolar depression) and schizophrenia in adults. The contraindication was added because of “the potential for serious and/or life-threatening reactions,” according to the FDA.

The labels on the following pharmaceutical products will be updated to reflect the change:

Aptivus (tipranavir)

Crixivan (indinavir)

Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide)

Invirase (saquinavir)

Kaletra (lopinavir/ritonavir)

Lexiva (fosamprenavir): Lurasidone is contraindicated because of the potential for serious and/or life-threatening reactions if fosamprenavir is coadministered with ritonavir.

Norvir (ritonavir)

Prezista (darunavir)

Reyataz (atazanavir): Lurasidone is contraindicated because of the potential for serious and/or life-threatening reactions if atazanavir is coadministered with ritonavir.

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)

Viracept (nelfinavir)

Labels for Evotaz (atazanavir/cobicistat) and Prezcobix (darunavir/cobicistat) already include a contraindication for lurasidone, the FDA announcement noted.

rpizzi@frontlinemedcom.com

On Twitter @richpizzi

Ads